Aytu BioPharma, Inc. (AYTU)
$1.95-2.01%Close
SELLRECOVERY · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $16M
- Beta
- 0.27
- P/E (TTM)
- -1.42
- Short % float
- 4.54%
- Days to cover
- 4.7
- SI change
- +10.8%
- 1W
- -4.88%
- 1M
- -2.01%
- vs SPY 1W
- -3.90%
- vs SPY 1M
- -3.88%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 39
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-31.7%
REV YoY-
ROE-0.0%
EPS YoY-
ROA-13.6%
GROSS64
OP-14
NET-25
[VALUATION]
P/E TTM-1.42
P/E FWD-
SECTOR PE20.48
INDUSTRY PE19.11
P/B0.68
P/FCF-
EV/EBITDA-1.53
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E51.33
ALTMAN Z-
CURR RATIO1.13
ND/EBITDA-
BETA0.27
NET INCOME (TTM) < 0
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR0.3
TRADES66
[REGIME]FULL HISTORY
RECOVERY
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on AYTU?
- LOPJLB’s latest quantitative signal on Aytu BioPharma, Inc. (AYTU) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AYTU in?
- Aytu BioPharma, Inc. (AYTU) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aytu BioPharma, Inc. (AYTU) do?
- Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailore…